King's College London

NanoString Products Drive Breakthrough Cancer Research at the 2024 American Association of Cancer Research (AACR) Conference

Retrieved on: 
Thursday, April 4, 2024
Oncology, Health, Health Technology, Genetics, Research, Science, Biotechnology, Inflammation, Harvard Medical School, DSP, Development, Gene expression, Immunotherapy, IL-6, Triple-negative breast cancer, RNA, King's College London, Immunology, Tumor microenvironment, Cancer, University, NanoString Technologies, Senior, Biology, Abstract, Pancreatic cancer, Neoplasm, Research and development, Hospital, Cell, SMI, MD Anderson Cancer Center, Blind spot, Medical imaging

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.

Key Points: 
  • NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, will present at the 2024 meeting of the American Association of Cancer Research studies delving into metastatic brain tumors, triple-negative breast cancer, pancreatic cancer and dozens of other vital research areas.
  • The conference will be held in San Diego, April 5-10, 2024.
  • NanoString and its customers will showcase 110 posters and highlight its products in three oral presentations focusing on unique biological insights generated with its platforms.
  • “NanoString customers are using the highest plex protein and RNA spatial biology panels commercially available on cancer patient samples, making fundamental discoveries and answering key questions about patient response to advanced cancer therapies utilized today.

Sexual Health Supplement Market Size, Share & Trends Analysis Report 2024: Natural Ingredients Lead Market Amid Preference for Organic Products - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2024
Vitamins, Supplements, Other Health, Other Retail, Health, Retail, Dicarboxylic acid, Tablet, Prevalence, Human, Erectile dysfunction, Capsule, Application, COVID-19, Anxiety, Synthetic, NIH, King's College London, Parity, Nature, Safety, ED, Market, Dietary supplement

As per King's College London, ED is estimated that by 2025, 322 million men worldwide are expected to be affected by it.

Key Points: 
  • As per King's College London, ED is estimated that by 2025, 322 million men worldwide are expected to be affected by it.
  • Government-supported sexual health programs indeed have a significant impact on the market.
  • These programs help to increase awareness about sexual health issues, promote safe sex practices and encourage people to take proactive steps to maintain their sexual health.
  • For instance, Australia Department of Health has "Healthysexual" program, which raise awareness about sexual health.

Hyperfine, Inc. Collaborates with King’s College London to Demonstrate the Swoop® System and UNITY Project to The Princess Royal

Retrieved on: 
Tuesday, March 12, 2024
Research, Medical Devices, Neurology, Hospitals, Health Technology, Radiology, Health, General Health, Science, Mother, HRH, Princess Royal, Brain, King, MRI, Bill, Hyperfine structure, National Health Service, NHS, Ultra, Quality of life, King's College London, Multimedia, Royal Highness, FDA, School, Medical imaging

Her Royal Highness was shown a demonstration of the Swoop® system to see first-hand the device’s ease of use.

Key Points: 
  • Her Royal Highness was shown a demonstration of the Swoop® system to see first-hand the device’s ease of use.
  • “It is a great pleasure for us to introduce HRH Princess Royal to the UNITY project.
  • “Since 2021, the Hyperfine, Inc. collaboration with King’s College London has further enabled our vision of making brain MRI accessible anywhere in the world to become a reality at UNITY project sites,” said Ms. Sainz.
  • The center also provides National Health Service (NHS) services under the South London and Maudsley NHS Foundation Trust.

Government of Canada announces funding to help counter ideologically motivated violent extremism

Retrieved on: 
Tuesday, March 12, 2024
Public security, Government, International Centre, Organization, Global Television Network, Law enforcement, Research, Violent extremism, Doctor of Philosophy, Movement, READ, ICSR, King's College London, Domestic terrorism, Community engagement, Safety, CRF, Repository, Public Safety Canada, War studies, Drug

Housed at King's College London's International Centre for the Study of Radicalization and Political Violence (ICSR), the READ is a secured online repository of information about ideologically motivated violent extremism (IMVE).

Key Points: 
  • Housed at King's College London's International Centre for the Study of Radicalization and Political Violence (ICSR), the READ is a secured online repository of information about ideologically motivated violent extremism (IMVE).
  • It is designed to support in-depth work by researchers and practitioners to better understand forms of IMVE such as white supremacist, xenophobic, anti-authority, and gender-driven manifestations of violent extremism.
  • This funding will help improve understanding of violent extremism dynamics, as well as strengthen capacity to prevent violent radicalization and respond effectively to emerging threats through improved knowledge-sharing.
  • The Community Resilience Fund, led by Public Safety's Canada Centre, provides financial support to organizations working to improve Canada's understanding and capacity to prevent and counter violent extremism.

Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development

Retrieved on: 
Monday, March 4, 2024
Therapy, Pharmacology, Bachelor of Science, AstraZeneca, Biotechnology, Roche, University of Sunderland, Drug development, Postgraduate diploma, Inflammation, Hearing loss, King's College London, University, Middlesex University, DevOps, Ben, Patient, Drug, Management science, Head, Pharmaceutical industry

At Sitryx, Ben joins the Company’s senior leadership team and will oversee the Company’s day-to-day operations and finance.

Key Points: 
  • At Sitryx, Ben joins the Company’s senior leadership team and will oversee the Company’s day-to-day operations and finance.
  • Before becoming Head of Clinical Operations at Sitryx, Gordon was Vice President of Development Operations at biotech company Mission Therapeutics, where he oversaw the design and execution of the company’s clinical development assets.
  • Leading Sitryx’s clinical operations, Gordon will work with the development team as it progresses its assets beyond pre-clinical research and into clinical-stage drug development.
  • Dr Ravi Rao, Chief Medical Officer of Sitryx, commented: “Sitryx has made excellent progress with its pipeline of potential first- and best-in-class, disease-modifying therapeutics.

Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings

Retrieved on: 
Wednesday, February 28, 2024
Therapy, Workload, Breast cancer, Area, Odense University Hospital, Algorithm, Woman, Radiology, Pneumothorax, Artificial intelligence, AI, Research, Triage, Pathology, Deep learning, Use, AUC, Workflow, King's College London, NHS, ACV, ECR, Mammography, Radboud University Medical Center, Report, Patient, Poster, Human, Medical device

SEOUL, South Korea, Feb. 28, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of seven studies at the European Congress of Radiology (ECR) 2024, to be held in Vienna, Austria, from February 28 to March 3. Four will be presented through oral presentations and three as E-posters.

Key Points: 
  • Four out of seven AI products, including Lunit INSIGHT CXR, showed superior performance compared to human readers.
  • Lunit invites booth visitors at ECR 2024 to explore detailed information on the project and discuss potential future collaborations.
  • "We are proud to present our latest research findings at this year's ECR, demonstrating the robust performance and versatility of our Lunit INSIGHT suite in various clinical settings and scenarios.
  • Join Lunit at booth AI-15 in the EXPO X1 hall to witness how the Lunit INSIGHT suite is shaping the future of radiology across the globe.

New Research: Eating Almonds Can Aid in Post-Exercise Recovery

Retrieved on: 
Wednesday, February 21, 2024
Woman, Magnesium, Body composition, Senior lecturer, Overweight, Inflammation, Exercise, Muscle soreness, Potassium, Vitamin E, Frontiers, King's College London, Triglyceride, Nutrient, Fats, Creatine kinase, Athlete, C-reactive protein, Myopathy, Appetite, DV, Research, Public, Dietary supplement

MODESTO, Calif., Feb. 21, 2024 /PRNewswire/ -- A new study found that eating almonds reduced some feelings of muscle soreness during exercise recovery which translated to improved muscle performance during a vertical jump challenge. These results expand on prior research1 which looked at how almonds affect muscle recovery after exercise.

Key Points: 
  • These results expand on prior research1 which looked at how almonds affect muscle recovery after exercise.
  • The treadmill test was designed to cause muscle damage to see how almonds affected muscle recovery.
  • Study Conclusion: Snacking on almonds for eight weeks reduced perceived feelings of muscle soreness during recovery from muscle-damaging exercise, resulting in better maintenance of muscle functional capacity.
  • This study suggests that almonds are a functional food snack to improve exercise tolerance in mildly overweight, middle-aged adults.

LATHAM & WATKINS ELECTS 19 NEW PARTNERS

Retrieved on: 
Tuesday, February 20, 2024
Virginia School for Girls, Project, Investment, Tulane University Law School, Second, Lawsuit, Government, BPP Law School, LLM, University, LLB, Biotechnology, Marketing, Airport, Oberlandesgericht, Bankruptcy, LPC, Brigham Young University, Sheva Alomar, Partnership, Latham & Watkins, College, Public company, King's College London, Columbia Law School, Competition law, JD, Patent, JD-MBA, Environment, George Washington University, Graduate diploma, Mergers and acquisitions, University School, Ministry of Finance, Corporate law, Saint Joseph University, Intellectual property

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Latham & Watkins LLP1 is pleased to announce that 19 counsel have been elected to the partnership, effective March 1. Each delivers exceptional advice and service to clients in distinct areas of practice.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Latham & Watkins LLP1 is pleased to announce that 19 counsel have been elected to the partnership, effective March 1.
  • "I am tremendously proud of our newest partners, whose legal skills, commitment to client service, and dedication to teamwork epitomize what it means to be a Latham partner.
  • We're excited about their continued success and the substantial contributions they will bring to our firm and our clients," said Rich Trobman, Chair and Managing Partner of Latham & Watkins.
  • The counsel who have been elected partners are:
    Joshua Bledsoe (Orange County) is a member of the Environment, Land & Resources Practice and Corporate Department.

New Initiative Launched to Accelerate the Use of AI in the Fight Against Neurodegenerative Diseases

Retrieved on: 
Tuesday, February 13, 2024
Master of Science, Artificial intelligence, AI, Gates Ventures, Rain, Richard Rainwater, Partnership, Health, SPARC, MBA, Neurodegenerative disease, Business development, King's College London, Prevalence, Patient, Milken Institute, Harvard Business School, Research, Parkinson's disease, Brain, Medical device

OAKLAND, Calif., Feb. 13, 2024 /PRNewswire/ -- The 10,000 Brains Project, an independent 501(c)(3) nonprofit organization, has been launched to promote the ethical use of artificial intelligence (AI) in the fight against Alzheimer's, Parkinson's, and other neurodegenerative diseases. The organization's mission is to provide the leadership, expertise, and financial support needed to ensure that researchers can rapidly adopt this powerful new technology in the search for better diagnostics and treatments for patients in need.

Key Points: 
  • Neurodegeneration is perhaps the most complex challenge in healthcare and the development of treatments has proven resistant to traditional research methods.
  • Patrick Brannelly, a seasoned executive in nonprofit and entrepreneurial ventures, has been named the founding CEO of The 10,000 Brains Project.
  • We are excited to build a research roadmap that will show how private funding can accelerate this important area of medical research."
  • First, solving neurodegenerative diseases will require researchers to recognize the full diversity of human brains; every person's brain is different, and their disorders can take a variety of different paths.

Leading Journal Unveils Groundbreaking Efficacy of Novel Treatment for Obesity, Diabetes, and Liver Disease

Retrieved on: 
Thursday, January 18, 2024
Obesity, DSM-IV codes, Patient, Weight gain, Overalls, MASH, Bypass surgery, Insulin, Safety, King's College London, Glucose, Liver, BMI, Stomach, Gastroenterology, Endoscopy, Medical device

The study, authored by an international team of prominent researchers, appeared in Gut, which is the leading international journal in the field of gastroenterology.

Key Points: 
  • The study, authored by an international team of prominent researchers, appeared in Gut, which is the leading international journal in the field of gastroenterology.
  • Substantial improvements in how the body handles insulin and reduces glucose in the liver compared to controls.
  • Markedly improved response to insulin, enhanced overall body’s use of glucose, and beneficial changes in metabolic health-related gut bacteria.
  • Should the upcoming trials, as anticipated, confirm the safety and efficacy demonstrated in animal studies, this device is poised to transform the treatment of severe and morbid obesity in the years ahead.